Biocardia stock.

Analysts who follow BioCardia Inc on average expect it to increase 1150.00% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns BioCardia Inc an Analyst Ranking of 25, which means it ranks higher than 25 of stocks, based on data compiled by InvestorsObserver.BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 14d Why Beyond Air Shares Are Trading Lower By Around 37%?Convert Biocardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple. wise. Select a currency. USD. NASDAQ: Biocardia Inc ( BCDA) = 0.71 USD. Provided by Alpha Vantage.Nov 20, 2023 · The stock of BioCardia Inc. (BCDA) has seen a 84.85% increase in the past week, with a 84.37% gain in the past month, and a -16.66% decrease in the past quarter. The volatility ratio for the week is 30.21%, and the volatility levels for the past 30 days are at 12.77% for BCDA. The simple […] About BioCardia. BioCardia, Inc., headquartered in Sunnyvale, California, is a developer of two biotherapeutic platforms – the CardiAMP autologous bone marrow derived mononuclear cell therapy for cardiovascular indications, and the NK1R+ allogeneic bone marrow derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases.

SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor …Latest BioCardia Inc Stock News. As of October 04, 2023, BioCardia Inc had a $8.9 million market capitalization, putting it in the 12th percentile of companies in the Biotechnology & Medical Research industry. BioCardia Inc does not have a meaningful P/E due to negative earnings over the last 12 trailing months.

Get the latest BioCardia Inc (BCDA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

BioCardia (BCDA) stock price prediction is 0.57916802735395 USD. The BioCardia stock forecast is 0.57916802735395 USD for 2024 December 01, Sunday; ...BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 18d Why Beyond Air Shares Are Trading Lower By Around 37%?The estimated Net Worth of Peter Altman is at least $883 Thousand dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $205,985 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer, and Director at BioCardia.The estimated Net Worth of Peter Altman is at least $875 mil dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $197,402 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer y Director at BioCardia.

Nov 14, 2023 · BioCardia ( NASDAQ: BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical trial of its CardiAMP autologous cell therapy for the ...

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq ...

BioCardia ( NASDAQ: BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical trial of its CardiAMP autologous cell therapy for the ...SAN CARLOS, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- BioCardia ®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, today reported financial results for the first quarter of 2021 and filed its quarterly report on Form 10-Q for the three months …Nov 29, 2023 · BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 18d Why Beyond Air Shares Are Trading Lower By Around 37%? BioCardia announces $1.3M registered direct offering priced at-the-market. Track BioCardia Inc. (BCDA) Stock Price, Quote, latest community messages, chart, news …BioCardia stock has received a consensus rating of buy. The average rating score is and is based on 9 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for BioCardia stock?Jul 24, 2023 · July 24, 2023. SUNNYVALE, Calif. – BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP ...

Nov 24, 2023 · BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmo... A new COVID variant, HV.1, is now dominant. These are its most common symptoms. Deer hunting is dying. That should worry you even if you don't hunt. The FDA approved BioCardia Inc's (NASDAQ: BCDA ...Website. n/a. 33. Peter Altman. https://www.biocardia.com. BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of ...BioCardia Inc BCDA shares are down after the company released interim efficacy results in the phase 3 pivotal CardiAMP cell therapy heart failure trial.. For the first tier, all-cause death ...The gross proceeds to BioCardia, before deducting fees and other offering expenses, are expected to be approximately $3.6 million. The closing of the sale of the securities is expected to occur on ...Discover historical prices for BCDA stock on Yahoo Finance. View daily, weekly or monthly format back to when BioCardia, Inc. stock was issued. Full Company Report for BCDA. View BioCardia, Inc BCDA investment & stock information. Get the latest BioCardia, Inc BCDA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Peter Altman became the CEO of BioCardia, Inc. (NASDAQ:BCDA) in 2002, and we think it's a good time to look at the...2023 BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023 24 Jul 2023 BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected

Nov 14, 2023 · BioCardia ( NASDAQ: BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical trial of its CardiAMP autologous cell therapy for the ... BioCardia announces $1.3M registered direct offering priced at-the-market. Track BioCardia Inc. (BCDA) Stock Price, Quote, latest community messages, chart, news …Biocardia. stock was originally listed at a price of $1,738.17 in Dec 31, 1997. If you had invested in Biocardia stock at $1,738.17, your return over the last 25 years would have been -99.96%, for an annualized return of -27.08% (not including any dividends or dividend reinvestments).SUNNYVALE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...Sep 5, 2023 · The treated group median 6MWT at 12M increased 36.1 with a standard deviation of ±70.8 meters, and the control group median 6MWT increased at 12M by 33.4 meters ± 74.8 meters (p =0.6). Results ... The treated group median 6MWT at 12M increased 36.1 with a standard deviation of ±70.8 meters, and the control group median 6MWT increased at 12M by 33.4 meters ± 74.8 meters (p =0.6). Results ...Find the latest BioCardia, Inc. (BCDA) stock quote, history, news and other vital information to help you with your stock trading and investing. BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -15.27% Nov-15-23 …Stock analysis for BioCardia Inc (BCDA:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Discover historical prices for BCDA stock on Yahoo Finance. View daily, weekly or monthly format back to when BioCardia, Inc. stock was issued.

2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval 16 Nov 2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

Complete BioCardia Inc. stock information by Barron's. View real-time BCDA stock price and news, along with industry-best analysis.Reported on 11/7/23. Get the latest BioCardia Inc (BCDA) real-time quote, historical performance, charts, and other financial information to help you make more informed …According to one analyst, the rating for BCDA stock is "Strong Buy" and the 12-month stock price forecast is $4.0.BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive ...Allan Tessler BCDA stock SEC Form 4 insiders trading. Allan has made over 11 trades of the BioCardia stock since 2006, according to the Form 4 filled with the SEC. Most recently Allan bought 400 units of BCDA stock worth $199,200 on 9 March 2020.400 units of BCDA stock worth $199,200 on 9 March 2020.SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...SUNNYVALE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -15.27% Nov-15-23 …

The estimated Net Worth of Simon H Stertzer is at least $1.55 Миллион dollars as of 5 July 2019. Simon Stertzer owns over 166,666 units of BioCardia stock worth over $1,476,667 and over the last 6 years he sold BCDA stock worth over $0. In addition, he makes $76,250 as Independent Chairman of the Board at BioCardia.SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...The Wall Street analyst predicted. that Biocardia's share price could reach $4.00 by Nov 14, 2024. The average Biocardia stock price prediction forecasts a potential upside of 495.24% from the current BCDA share price of $0.67. Instagram:https://instagram. best trade coursesbest banks in virginiahighest yield reitwsj plus Discover historical prices for BCDA stock on Yahoo Finance. View daily, weekly or monthly format back to when BioCardia, Inc. stock was issued. gainer loser stockoriginal ipod Exhibit 4.1 [Director Deferred Settlement—Fixed Date] BIOCARDIA, INC. 2016 EQUITY INCENTIVE PLAN. RESTRICTED STOCK UNIT AGREEMENT . Unless otherwise defined herein, the terms defined in the BioCardia, Inc. 2016 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement (the “Award … what is eps in shares 16 Nov 2023 ... BioCardia develops cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. Stock BCDA logo. BioCardia ...Nov 15, 2023 · BioCardia (NASDAQ:BCDA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better investment?We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation. SAN CARLOS, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for ...